Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) CFO Sells 3,250 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,250 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $20.40, for a total value of $66,300.00. Following the completion of the sale, the chief financial officer owned 23,000 shares in the company, valued at approximately $469,200. This represents a 12.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Benjamin Hohl also recently made the following trade(s):

• On Wednesday, August 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.63, for a total transaction of $67,047.50.
• On Monday, July 28th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.46, for a total transaction of $66,495.00.
• On Thursday, July 10th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.66, for a total transaction of $22,660.00.

Enliven Therapeutics Stock Performance

ELVN opened at $19.83 on Thursday. The company has a fifty day moving average of $19.70 and a two-hundred day moving average of $19.60. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -9.92 and a beta of 0.85. Enliven Therapeutics, Inc. has a fifty-two week low of $13.30 and a fifty-two week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Wednesday, August 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.04. On average, equities research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its holdings in shares of Enliven Therapeutics by 3,058.1% during the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company’s stock worth $53,000 after buying an additional 2,630 shares in the last quarter. Quantbot Technologies LP purchased a new stake in Enliven Therapeutics during the 1st quarter valued at about $60,000. BNP Paribas Financial Markets raised its holdings in Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after acquiring an additional 930 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Enliven Therapeutics by 194.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock worth $106,000 after purchasing an additional 3,490 shares in the last quarter. Finally, KLP Kapitalforvaltning AS boosted its holdings in shares of Enliven Therapeutics by 58.1% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock worth $136,000 after purchasing an additional 2,500 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. HC Wainwright raised their price objective on Enliven Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, July 2nd. Robert W. Baird lifted their price target on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday, June 16th. Finally, The Goldman Sachs Group began coverage on shares of Enliven Therapeutics in a research report on Monday, June 16th. They set a “buy” rating and a $37.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Enliven Therapeutics presently has an average rating of “Buy” and a consensus price target of $41.20.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.